EGFR and non-small cell lung carcinoma: Growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), which include the drugs gefitinib and erlotinib, have shown potential in improving disease-free survival (DFS) for NSCLC patients with EGFR mutations.